ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based,
nutraceutical company devoted to improving the way people age,
announced the launch of TRU NIAGEN™ in Singapore with its retail
partner, Watsons. Singapore is the second Asian market for the U.S.
made dietary supplement, after Hong Kong.
With over 6,000 stores in 11 Asian and European markets, Watsons
is the leading health and beauty retailer in Asia and Europe. On
Jan. 4, Watsons introduced TRU NIAGEN™ in stores in Singapore and
online at www.watsons.com.sg. A launch event is scheduled for Jan.
10.
Robert Fried, President and Chief Strategy Officer of ChromaDex,
remarks, “We are grateful to be working with Watsons to make TRU
NIAGEN™ available in Singapore. Our successful experience in Hong
Kong has made quite clear to us why the Watsons organization is so
well respected.”
The key ingredient in TRU NIAGEN™ is NIAGEN® nicotinamide
riboside, a cutting-edge form of vitamin B3 proven to significantly
increase NAD+ levels. Maintenance of sufficient levels of NAD+ is
key to cellular energy metabolism and mitochondrial
function.
Ms. Irene Lau, Chief Operating Officer of Watsons Singapore,
shared: “Singapore is feeling the impact of a rapidly aging
population and that comes with a set of needs to lead healthier
lives. At Watsons, we want to be able to meet that need and bring
market-leading health products that can better the lives of
Singaporeans. TRU NIAGEN™ provides nutritional support and has
proven effectiveness in raising levels of NAD+ which may slow cell
dysfunction and help us achieve optimal health.”
Frank Jaksch, Jr., CEO and Co-founder of ChromaDex added, “We
are excited to bring this healthy aging technology to the people of
Singapore—this is an important milestone in our global
expansion.”
TRU NIAGEN™ will be available at a single bottle price of
S$69.90 and a three bottle price of S$178.25.
To date, ChromaDex has invested millions in analytical research,
toxicology studies and human clinical trials supporting the safety
and efficacy of TRU NIAGEN™. It has initiated over 130
collaborative studies with leading universities and research
institutions, representing an estimated $50+ million in additional
nicotinamide riboside research.
For more information on ChromaDex, visit:
https://www.chromadex.com/.
About TRU NIAGEN™ TRU NIAGEN™ is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the feature
ingredient in TRU NIAGEN™. Research published in Nature
Communications demonstrates it is clinically proven to boost NAD+
(nicotinamide adenine dinucleotide) levels, which decline with age.
Only NIAGEN® nicotinamide riboside has Generally Recognized as Safe
(GRAS) status and a New Dietary Ingredient Notification (NDIN),
both reviewed by FDA.
About ChromaDex:ChromaDex Corp. is an
integrated, global nutraceutical company devoted to improving the
way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD+ and identify and develop novel,
science-based ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside, sold directly to consumers as TRU NIAGEN™,
is backed with clinical and scientific research, as well as
extensive IP protection. TRU NIAGEN™ is helping the world AGE
BETTER®. To learn more about ChromaDex, please visit
www.chromadex.com.
About Watsons Singapore
Watsons is Singapore’s leading beauty and health retailer with
more than 100 stores located islandwide. Aligned with its
philosophy of bringing ‘more’ to customers’ lives, Watsons inspires
and enables every one of our customers to look good and feel great
so they can enjoy life to the fullest. A strong advocate of
preventive care, Watsons has also enhanced its health platform with
38 pharmacies located within its key stores, offering services such
as medication dispensing and review, health screening packages and
counselling on smoking cessation and minor ailments. Watsons
clinched the top spot for ‘Personal Care Store’, ‘Best Retail
Loyalty Card’ and 'No. 1 Multi-Brand Beauty Store' for Asia’s Top
Influential Brands 2016 by Brand Alliance, based on Singapore
consumers’ choices.
About NAD+NAD+ activates cellular metabolism
and energy production within the cell’s “power stations,” the
mitochondria. Our mitochondria are constantly working to convert
the food we eat into the energy necessary to power all bodily
systems as well as help us stay healthy. The challenge is that both
NAD+ levels and mitochondrial functions decline as we age. This
reduction in NAD+ is believed by scientists to be linked to a wide
variety of age-related challenges.
Forward-Looking Statements:This release
contains forward-looking statements relating to ChromaDex and
ChromaDex’s business within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended, including
statements related to the timing and expansion plans of launching
TRU NIAGEN™ in Asia, the ability of ChromaDex to execute on
expanding TRU NIAGEN™ sales, whether science will reinforce how
important NAD+ and TRU NIAGEN™ are to health, the health benefits
of TRU NIAGEN™, including whether TRU NIAGEN™ can help consumers
achieve health longevity, the amount ChromaDex will invest in
trials supporting the safety and efficacy of TRU NIAGEN™, the price
of TRU NIAGEN™ to consumers in Asia and whether a reduction in NAD+
is linked to age-related challenges. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2016,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
ChromaDex Media Contact: Alex Worsham, Director of Strategic
Partnerships 949-648-3775 alexw@chromadex.com ChromaDex Investor
Relations Contact: Andrew Johnson, Director of Investor Relations
949-419-0288 andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024